MX2022001742A - Metodos para prevenir el dengue y la hepatitis a. - Google Patents

Metodos para prevenir el dengue y la hepatitis a.

Info

Publication number
MX2022001742A
MX2022001742A MX2022001742A MX2022001742A MX2022001742A MX 2022001742 A MX2022001742 A MX 2022001742A MX 2022001742 A MX2022001742 A MX 2022001742A MX 2022001742 A MX2022001742 A MX 2022001742A MX 2022001742 A MX2022001742 A MX 2022001742A
Authority
MX
Mexico
Prior art keywords
dengue
hepatitis
tdv
methods
preventing dengue
Prior art date
Application number
MX2022001742A
Other languages
English (en)
Inventor
Derek Wallace
Original Assignee
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP19195692.9A external-priority patent/EP3620174B1/en
Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc
Publication of MX2022001742A publication Critical patent/MX2022001742A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La invención se refiere a un método para prevenir el dengue y la hepatitis A en un sujeto o una población de sujetos mediante la administración simultánea, el mismo día, de una dosis unitaria de una composición vacunal contra el dengue y una vacuna contra la hepatitis A. La dosis unitaria de una composición vacunal contra el dengue incluye construcciones de cada serotipo de dengue, como TDV-1, TDV-2, TDV-3 y TDV-4, a diversas concentraciones para mejorar la protección frente a la infección de dengue.
MX2022001742A 2019-08-16 2020-03-04 Metodos para prevenir el dengue y la hepatitis a. MX2022001742A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IDP00201907241 2019-08-16
EP19195692.9A EP3620174B1 (en) 2018-09-05 2019-09-05 Dengue vaccine unit dose and administration thereof
PCT/US2019/049749 WO2020051334A1 (en) 2018-09-05 2019-09-05 Dengue vaccine unit dose and administration thereof
US16/561,953 US11590221B2 (en) 2018-09-05 2019-09-05 Dengue vaccine unit dose and administration thereof
PCT/US2020/020991 WO2021034349A1 (en) 2019-08-16 2020-03-04 Methods for preventing dengue and hepatitis a

Publications (1)

Publication Number Publication Date
MX2022001742A true MX2022001742A (es) 2022-04-07

Family

ID=74660757

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001742A MX2022001742A (es) 2019-08-16 2020-03-04 Metodos para prevenir el dengue y la hepatitis a.

Country Status (9)

Country Link
EP (1) EP4013451A1 (es)
JP (1) JP2022544613A (es)
KR (1) KR20220049023A (es)
CN (1) CN114555113A (es)
AU (1) AU2020331884A1 (es)
BR (1) BR112022001476A2 (es)
CA (1) CA3147807A1 (es)
MX (1) MX2022001742A (es)
WO (1) WO2021034349A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024097725A1 (en) * 2022-11-02 2024-05-10 Takeda Vaccines, Inc. A method for determining the infectivity of a virus

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4504464B2 (ja) 1997-02-28 2010-07-14 サノフィ パスツール バイオロジクス カンパニー キメラフラビウイルスワクチン
AU2003239932A1 (en) 2002-05-31 2003-12-19 Acambis, Inc. Tetravalent dengue vaccines
EP1924280A4 (en) 2005-08-10 2008-12-10 Acambis Inc VACCINATION AGAINST DENGUE VIRUS INFECTION
FR2903605A1 (fr) 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
AU2007285929B2 (en) 2006-08-15 2013-09-05 Goverment Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The Development of dengue virus vaccine components
FR2906724B1 (fr) 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
FR2909286B1 (fr) 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
WO2014093182A1 (en) * 2012-12-14 2014-06-19 Inviragen, Inc. Compositions, methods of administration and uses for trivalent dengue virus formulations
EP3188751A1 (en) 2014-09-02 2017-07-12 Sanofi Pasteur Vaccine compositions against dengue virus diseases
EP3442571A1 (en) * 2016-04-13 2019-02-20 Takeda Vaccines, Inc. Compositions and methods of vaccination against dengue virus in children and young adults
TWI766876B (zh) 2016-08-03 2022-06-11 美商武田疫苗股份有限公司 用於與經改良之調配物一起穩定黃病毒的組成物及方法

Also Published As

Publication number Publication date
BR112022001476A2 (pt) 2023-10-03
EP4013451A1 (en) 2022-06-22
KR20220049023A (ko) 2022-04-20
AU2020331884A1 (en) 2022-03-03
CN114555113A (zh) 2022-05-27
JP2022544613A (ja) 2022-10-19
CA3147807A1 (en) 2021-02-25
WO2021034349A1 (en) 2021-02-25

Similar Documents

Publication Publication Date Title
PH12021550479A1 (en) Dengue vaccine unit dose and administration thereof
BR112018005454A2 (pt) administração de potencializadores de cftr deuterados
PH12018550201A1 (en) Hepatitis b antiviral agents
CY1122648T1 (el) Διαδικασια για την παρασκευη συνθεσεων που περιεχουν υαλουρονικο οξυ και υδροχλωρικη μεπιβακαϊνη
UY37997A (es) Agentes antivirales contra la hepatitis b
EA201992784A1 (ru) Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
BR112018013387A2 (pt) vetor de vacinação recombinante, vírus mva, vacina ou composição farmacêutica e kit
MY169275A (en) Method of immunization against the four serotypes of dengue
EA201992334A1 (ru) Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
MY202109A (en) Viral replication inhibitors
PH12015502230A1 (en) Novel viral replication inhibitors
MX2009003417A (es) Metodo de inmunizacion contra los 4 serotipos de dengue.
MY195194A (en) Substituted Indoline Derivatives as Dengue Viral Replication Inhibitors
EA201992782A1 (ru) Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
CR20220215A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
EA201990010A1 (ru) Вакцина против вируса инфекционного бронхита
BR112018011622A2 (pt) método para tratar ataque de angioedema hereditário (hae) ou reduzir a taxa de ataque de hae
EA201991041A1 (ru) Вакцина против свиного парвовируса и вируса свиного репродуктивного и респираторного синдрома и способы ее получения
MX2022006742A (es) Uso y composicion farmaceutica de derivados de fenilisoxazolil metilen-naftaleno-eter.
EA202191145A1 (ru) Вакцина виб 4/91 с гетерологичным шиповидным белком
PH12015502128A1 (en) Novel dosing regimens of celgosivir for the treatment of dengue
MX2022001742A (es) Metodos para prevenir el dengue y la hepatitis a.